Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 14, 2023

Primary Completion Date

May 26, 2025

Study Completion Date

May 26, 2025

Conditions
Thyroid Eye Disease
Interventions
DRUG

lonigutamab

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Trial Locations (11)

2109

Clinical Research Site, Sydney

3002

Clinical Research Site, East Melbourne

4102

Clinical Research Site, Woolloongabba

5000

Clinical Research Site, Adelaide

6009

Clinical Research Site, Nedlands

10028

Clinical Research Site, New York

11733

Clinical Research Site, East Setauket

26505

Clinical Research Site, Morgantown

30328

Clinical Research Site, Atlanta

32216

Clinical Research Site, Jacksonville

48108

Clinical Research Site, Ann Arbor

All Listed Sponsors
lead

ACELYRIN Inc.

INDUSTRY